THE EORTC EARLY CLINICAL-TRIALS COOPERATIVE GROUP EXPERIENCE WITH 5-AZA-2'-DEOXYCYTIDINE (NSC-127716) IN PATIENTS WITH COLO-RECTAL, HEAD AND NECK, RENAL CARCINOMAS AND MALIGNANT MELANOMAS
THE EORTC EARLY CLINICAL-TRIALS COOPERATIVE GROUP EXPERIENCE WITH 5-AZA-2'-DEOXYCYTIDINE (NSC-127716) IN PATIENTS WITH COLO-RECTAL, HEAD AND NECK, RENAL CARCINOMAS AND MALIGNANT MELANOMAS
复制标题
DOI：
10.1016/0277-5379(87)90060-5
复制
发表时间：
1987-12-01
期刊：
影响因子：
--
通讯作者：
PINEDO, HM
中科院分区：
文献类型：
--
作者：
ABELE, R;CLAVEL, M;PINEDO, HM
EORTC 的早期临床试验合作组利用脱氧胞苷的嘧啶类似物 5-aza-2''-脱氧胞苷 (DAC) 进行了多项 II 期研究。该药物连续 1 h 静脉注射 3 次。输注75 mg/m2，间隔7小时；每 5 周重复一次课程。总共有 101 名符合条件的患者接受了研究：42 名患有直肠腺癌，27 名患有头颈部鳞状细胞癌，18 名患有恶性黑色素瘤，14 名患有肾细胞癌。药物引起的毒性包括中度骨髓抑制、恶心和呕吐。在一名恶性黑色素瘤患者中观察到一次部分缓解。以这种剂量和时间表给予的 DAC 对于患有这些难治性癌症的成年患者缺乏抗肿瘤活性。
The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2''-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligibile patients were studied: 42 with coo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumor activity in adult patients with these refractory types of carcinomas.